Vir Biotechnology Inc (VIR)

Debt-to-capital ratio

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019
Long-term debt	US$ in thousands	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Total stockholders’ equity	US$ in thousands	1,590,240	1,675,080	1,810,210	1,970,760	2,077,960	2,149,860	1,952,010	2,001,010	1,431,850	876,274	737,325	650,951	716,852	812,355	563,779	380,333	423,942	-280,797
Debt-to-capital ratio		0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	—

December 31, 2023 calculation

Debt-to-capital ratio = Long-term debt ÷ (Long-term debt + Total stockholders’ equity)
= $—K ÷ ($—K + $1,590,240K)
= 0.00

Based on the data provided for Vir Biotechnology Inc, the debt-to-capital ratio has consistently been reported as 0.00 across all quarters from Q1 2022 to Q4 2023. This indicates that the company has not reported any debt in relation to its capital structure during this period. A debt-to-capital ratio of 0.00 suggests that the company is not utilizing debt financing to fund its operations or investments. This could be viewed positively as it may indicate a lower financial risk and less financial leverage, which could potentially enhance the company's financial stability and flexibility. However, it is important to consider the context of the industry and company-specific circumstances when interpreting this ratio and assessing the overall financial health of Vir Biotechnology Inc.